LI-COR expansion offers early-phase cGMP services

By Flora Southey

- Last updated on GMT

Li-COR in Nebraska
Li-COR in Nebraska

Related tags Dna Molecular biology

LI-COR Biosciences has expanded its production facility to offer contract manufacturing for early-phase cGMP materials.

The facility in Lincoln, Nebraska currently produces reagents and dyes for surgery.

As a result of the expansion - financial terms of which were not provided - it will now offer synthesis and conjugation services for the production of early-phase materials for trials.

Bambi Reynolds, senior business development manager, said the expansion will help “researchers and biotechs to conjugate fluorophores to their specific biomolecules​.”

Reynolds added: “We have expanded our production facility to accommodate contract manufacturing for both pre-clinical and early phase clinical applications​.”

She also said demand for LI-COR dye used during fluorescent-guided intra-operative surgery had increased.

Dye history

LI-COR (previously Lambda Instruments Corporation) was founded in 1971.

The company focuses on biological and environmental sciences, with documented experience in global climate change, cancer research, and small animal imaging.

LI-COR was one the first biotechnology companies to use near-infrared (NIR) technology as a detection method.

Near-infrared DNA sequencing technology was initiated by LI-COR in the early ‘90s, which prompted pre-clinical developments including protein and small animal NIR imaging.

These developments led to the introduction of two NIR dyes into the clinical trials using targeted NIR as a method for detecting and treating various cancer types. 

Related news

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers